Safety and dosing study of ASP5541 in Chinese men with metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called ASP5541 for Chinese men with prostate cancer that has spread. The drug is given as a shot, and researchers want to see if it is safe and what the right dose might be.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to other parts of the body (metastatic).
- Your cancer is either hormone-sensitive (mHSPC) or has stopped responding to hormone therapy (mCRPC).
- You are currently on hormone therapy (or have had your testicles removed).
- You have no serious heart problems, active brain metastases, or other uncontrolled illnesses.
- You have not had certain cancer treatments or medications within the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.